Retrophin Announces Topline Results from Phase 3 FORT Study

Retrophin (NASDAQ:RTRX) has announced that the Phase 3 FORT study evaluating the safety and efficacy of fosmetpantotenate compared to a...

Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs...

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.

Kalytera Issues CEO Letter to Shareholders

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President...

Pharmaceutical Update: Q1 in Review

What happened in Q1 2018 for the pharma industry? Here's a look back at some of the quarter's biggest news...

Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA

Flexion Therapeutics (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone...

Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease

Kalytera Therapeutics, Inc. (TSXV:KALY. OTCQB:KALTF) announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,889,100 B2...